Evidence map›Paper›PMID 41669682›Full record

ArticleFrontiers in pharmacology2026

Rhein protects against renal aging and fibrotic injury by multiple targets through inhibition of TNF-α-mediated autophagy and necroptosis crosstalk.

Yue Tu, Wenjie Liu, Tianqing Sang, Liuyunxin Pan, Wei Wu, Qijun Fang, Yinglu Liu, Buhui Liu, Yigang Wan

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yue Tu *Department of Traditional Chinese Medicine Health Preservation, Acupuncture, Moxibustion and Massage College, Health Preservation and Rehabilitation College, Nanjing University of Chinese Medicine, Nanjing, China.
Wenjie Liu *Department of Traditional Chinese Medicine Health Preservation, Acupuncture, Moxibustion and Massage College, Health Preservation and Rehabilitation College, Nanjing University of Chinese Medicine, Nanjing, China.
Tianqing Sang *Department of Traditional Chinese Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Liuyunxin PanDepartment of Traditional Chinese Medicine Health Preservation, Acupuncture, Moxibustion and Massage College, Health Preservation and Rehabilitation College, Nanjing University of Chinese Medicine, Nanjing, China.
Wei WuDepartment of Traditional Chinese Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Qijun FangDepartment of Traditional Chinese Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Yinglu LiuDepartment of Traditional Chinese Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Buhui Liu *Department of Anatomy, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, China.
Yigang Wan *Institute of Chinese Medicine, Nanjing University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Rhein, an anthraquinone derived from rhubarb, exhibits renoprotective effects in aging and kidney injury; however, the mechanistic interplay with TNF-α-mediated cell death pathways remains undefined. Methods: Using D-galactose (D-gal)-treated NRK-52E cells and aged rats, we assessed rhein's effects with/without mTOR regulators (rapamycin/MHY1485) or etanercept (TNF-α inhibitor). Protein levels of klotho, phosphorylated (p)-mTOR, p-p62, caspase-8, beclin1, light chain 3 II, receptor-interacting protein kinase (RIPK)1, RIPK3, and p-mixed lineage kinase-like (MLKL) were measured. The concentration of reactive oxygen species (ROS) and the staining for senescence-associated-β-galactosidase (SA-β-gal) were also assessed. The network framework of "rhein-target-pathways" was identified. Additionally, serum untargeted metabolomics and KEGG pathway analysis were performed to identify altered metabolites and underlying metabolic pathways. Results: The results indicated that rhein increased the protein levels of klotho, p-mTOR, p-p62, and caspase-8, as well as decreased the concentration of ROS, the staining for SA-β-gal, and the protein levels of beclin1, light chain 3 II, RIPK1, RIPK3, and p-MLKL in NRK-52E cells exposed to D-gal. Compared to mTOR regulators (rapamycin or MHY1485) alone, the co-treatment of rhein and mTOR regulators decreased mTOR-mediated autophagy signaling in NRK-52E cells treated by D-gal. In addition, rhein decreased tumor necrosis factor (TNF)-α and TNF-α receptor1 protein levels. Interestingly, the effects of etanercept in TNF-α-mediated necroptosis and autophagy were similar to those of rhein. Consistent with the in vitro findings, rhein alleviated oxidative stress and exerted renal protective effects in aged model rats. Serum untargeted metabolomic analysis revealed that rhein treatment significantly altered 85 metabolites compared to the model group rats, with 35 metabolites upregulated and 50 downregulated. KEGG pathway analysis identified the TNF-α signaling pathway as a key metabolic pathway involved. Discussion: In conclusion, rhein protected the kidneys by activating p-mTOR and downregulating TNF-α, necroptosis and autophagy. Rhein mitigates renal aging and fibrotic injury by targeting TNF-α-mediated autophagy-necroptosis crosstalk, positioning it as a novel multi-target therapeutic agent for age-related kidney injury.

Indexed as

autophagynecroptosisrenal agingrenal fibrosisrheinTNF-α

Identifiers

PMID41669682
PMCPMC12883364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.